Top

Published in:

01-06-2018 | Original Article

Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients

Authors: Flávia Sayuri Matsuo, Marília Ferreira Andrade, Adriano Mota Loyola, Sindeval José da Silva, Marcelo José Barbosa Silva, Sérgio Vitorino Cardoso, Paulo Rogério de Faria

Published in: Virchows Archiv | Issue 6/2018

Abstract

Phosphatidylinositol-3-kinases are kinases that lead to AKT phosphorylation and thus mTOR and GSK3β activation. These proteins are linked to tumorigenesis, but their roles in driving cervical lymph node (CLN) metastasis of oral squamous cell carcinoma (OSCC) cells are unknown. This study aimed to investigate the role of AKT, mTOR, and GSK3β proteins in the occurrence of CLN metastasis in OSCC patients. Ninety and 18 paraffin-embedded OSCC and oral mucosa samples were included, respectively. We divided our OSCC patients into non-metastasizing (PNM) and metastasizing (PM) groups, and the expression of total AKT, pAKT1^Thr308, pAKT^Ser473, GSK3β, pGSK3β^Ser9, and pmTOR^Ser2448 was analyzed by immunohistochemistry. The mean expression of GSK3β, pGSK3β^Ser9, total AKT, and pmTOR²⁴⁴⁸ was always higher in the OSCC tissues than that in the controls. A positive correlation was also found among these proteins. Total AKT, pmTOR^Ser2448, and pGSK3β^Ser9 expression was significantly higher in the PNM and PM groups than that in the control group. However, only GSK3β expression was significantly higher in the PM group compared with the PNM group. High expression levels of GSK3β and pGSK3β^Ser9 were significantly associated with CLN metastasis, but only GSK3β remained an independent predictor of CLN metastasis. pGSK3β^Ser9 and CLN metastasis were associated with a poor prognosis, but only the latter remained an independent prognostic parameter. Kaplan-Meier survival curves showed that pGSK3β^Ser9 and CLN metastasis were significantly related to reduced survival rates. These results suggest that AKT and mTOR proteins are involved in OSCC biology and that GSK3β itself may drive CLN metastatic spread of OSCC cells.

Available only for authorised users

Simard EP, Torre LA, Jemal A (2014) International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol 50(5):387–403. https://doi.org/10.1016/j.oraloncology.2014.01.016 CrossRefPubMed

Genden EM, Ferlito A, Silver CE, Takes RP, Suarez C, Owen RP, Haigentz M Jr, Stoeckli SJ, Shaha AR, Rapidis AD, Rodrigo JP, Rinaldo A (2010) Contemporary management of cancer of the oral cavity. Eur Arch Otorhinolaryngol 267(7):1001–1017. https://doi.org/10.1007/s00405-010-1206-2 CrossRefPubMedPubMedCentral

Giudice FS, Squarize CH (2013) The determinants of head and neck cancer: unmasking the PI3K pathway mutations. J Carcinog Mutagen Suppl 5. doi:https://doi.org/10.4172/2157-2518.S5-003

Biazevic MG, Castellanos RA, Antunes JL, Michel-Crosato E (2006) Trends in oral cancer mortality in the city of Sao Paulo, Brazil, 1980-2002. Cad Saude Publica 22(10):2105–2114CrossRefPubMed

Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB (1994) Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 73(1):187–190CrossRefPubMed

Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, Gay EG, Langer CJ (2009) National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 31(6):748–758. https://doi.org/10.1002/hed.21022 CrossRefPubMed

Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR (2016) Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest 126(4):1606. https://doi.org/10.1172/JCI86862 CrossRefPubMedPubMedCentral

Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20(1):87–90. https://doi.org/10.1016/j.gde.2009.11.002 CrossRefPubMed

Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6(3):184–192. https://doi.org/10.1038/nrc1819 CrossRefPubMed

10.

Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562. https://doi.org/10.1038/nrc2664 CrossRefPubMed

11.

Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, Inazawa J (2006) PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 97(12):1351–1358. https://doi.org/10.1111/j.1349-7006.2006.00343.x CrossRefPubMed

12.

Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP, Su GH (2006) PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 12(5):1441–1446. https://doi.org/10.1158/1078-0432.CCR-05-2173 CrossRefPubMedPubMedCentral

13.

Fenic I, Steger K, Gruber C, Arens C, Woenckhaus J (2007) Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18(1):253–259PubMed

14.

Lim J, Kim JH, Paeng JY, Kim MJ, Hong SD, Lee JI, Hong SP (2005) Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 58(11):1199–1205. https://doi.org/10.1136/jcp.2004.024786 CrossRefPubMedPubMedCentral

15.

Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA (2005) Akt activation correlates with adverse outcome in tongue cancer. Cancer 104(11):2430–2436. https://doi.org/10.1002/cncr.21476 CrossRefPubMed

16.

Iamaroon A, Krisanaprakornkit S (2009) Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol 45(10):e175–e179. https://doi.org/10.1016/j.oraloncology.2009.06.003 CrossRefPubMed

17.

Zheng S, Yang C, Lu M, Liu Q, Liu T, Dai F, Gao X, Ilyar S, Lu X (2016) PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma. Hum Pathol 53:121–129. https://doi.org/10.1016/j.humpath.2015.11.013 CrossRefPubMed

18.

Du L, Shen J, Weems A, Lu SL (2012) Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol 2012:450179–450112. https://doi.org/10.1155/2012/450179 CrossRefPubMedPubMedCentral

19.

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501. https://doi.org/10.1038/nrc839 CrossRefPubMed

20.

Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9(6):667–676. https://doi.org/10.1023/B:APPT.0000045801.15585.dd CrossRefPubMed

21.

Moral M, Paramio JM (2008) Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 23(10):1269–1278PubMed

22.

Vander Broek R, Mohan S, Eytan DF, Chen Z, Van Waes C (2015) The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. Oral Dis 21(7):815–825. https://doi.org/10.1111/odi.12206 CrossRefPubMed

23.

Mendonca DF, Chammas R, Liu FT, Nonogaki S, Cardoso SV, Loyola AM, de Faria PR (2012) The inactive form of glycogen synthase kinase-3beta is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice. Int J Clin Exp Pathol 5(6):547–554PubMedPubMedCentral

24.

Mishra R (2010) Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 9:144. https://doi.org/10.1186/1476-4598-9-144 CrossRefPubMedPubMedCentral

25.

Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, Ralhan R (2009) Expression analysis of E-cadherin, slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer 9:325. https://doi.org/10.1186/1471-2407-9-325 CrossRefPubMedPubMedCentral

26.

Gao S, Li S, Duan X, Gu Z, Ma Z, Yuan X, Feng X, Wang H (2017) Inhibition of glycogen synthase kinase 3 beta (GSK3beta) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity. Mol Carcinog 56(10):2301–2316. https://doi.org/10.1002/mc.22685 CrossRefPubMed

27.

Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127(3):469–480. https://doi.org/10.1016/j.cell.2006.10.018 CrossRefPubMed

28.

Farago M, Dominguez I, Landesman-Bollag E, Xu X, Rosner A, Cardiff RD, Seldin DC (2005) Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res 65(13):5792–5801. https://doi.org/10.1158/0008-5472.CAN-05-1021 CrossRefPubMed

29.

Cardesa A, Gale N, Nadal A, Zidar N (2005) Tumors of the hypopharynx, larynx and trachea. In: Barnes L, Eveson JW, Reichart P, Sidransky D (eds) World Health Organization classification of tumors. Pathology and genetics of head and neck tumors. IARC, Lyon, pp 118–121

30.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847CrossRefPubMed

31.

Detre S, Saclani Jotti G, Dowsett M (1995) A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48(9):876–878CrossRefPubMedPubMedCentral

32.

Mishra R, Nagini S, Rana A (2015) Expression and inactivation of glycogen synthase kinase 3 alpha/beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression. Mol Cancer 14:20. https://doi.org/10.1186/s12943-015-0300-x CrossRefPubMedPubMedCentral

33.

Wang J, Wang X, Gong W, Mi B, Liu S, Jiang B (2009) Increased expression of beta-catenin, phosphorylated glycogen synthase kinase 3beta, cyclin D1, and c-myc in laterally spreading colorectal tumors. J Histochem Cytochem 57(4):363–371. https://doi.org/10.1369/jhc.2008.953091 CrossRefPubMedPubMedCentral

34.

Cortesina G, Martone T (2006) Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature. Acta Otorhinolaryngol Ital 26(6):317–325PubMedPubMedCentral

35.

McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, Cocco L, Martelli AM, Cervello M (2014) GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5(10):2881–2911. https://doi.org/10.18632/oncotarget.2037 CrossRefPubMedPubMedCentral

36.

Zheng HC, Xu XY, Xia P, Yu M, Takahashi H, Takano Y (2010) Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas. Hum Pathol 41(9):1255–1264. https://doi.org/10.1016/j.humpath.2010.02.003 CrossRefPubMed

37.

Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116(Pt 7):1175–1186CrossRefPubMedPubMedCentral

38.

Baltzis D, Pluquet O, Papadakis AI, Kazemi S, Qu LK, Koromilas AE (2007) The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. J Biol Chem 282(43):31675–31687. https://doi.org/10.1074/jbc.M704491200 CrossRefPubMed

39.

Acosta-Jaquez HA, Keller JA, Foster KG, Ekim B, Soliman GA, Feener EP, Ballif BA, Fingar DC (2009) Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol Cell Biol 29(15):4308–4324. https://doi.org/10.1128/MCB.01665-08 CrossRefPubMedPubMedCentral

40.

Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455–7464. https://doi.org/10.1038/sj.onc.1209085 CrossRefPubMed

41.

Wu HT, Ko SY, Fong JH, Chang KW, Liu TY, Kao SY (2009) Expression of phosphorylated Akt in oral carcinogenesis and its induction by nicotine and alkaline stimulation. J Oral Pathol Med 38(2):206–213. https://doi.org/10.1111/j.1600-0714.2008.00659.x CrossRefPubMed

42.

Clark C, Shah S, Herman-Ferdinandez L, Ekshyyan O, Abreo F, Rong X, McLarty J, Lurie A, Milligan EJ, Nathan CO (2010) Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope 120(6):1159–1165. https://doi.org/10.1002/lary.20917 PubMedPubMedCentralCrossRef

Title: Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients
Authors: Flávia Sayuri Matsuo
Marília Ferreira Andrade
Adriano Mota Loyola
Sindeval José da Silva
Marcelo José Barbosa Silva
Sérgio Vitorino Cardoso
Paulo Rogério de Faria
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 6/2018
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2318-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Extra-axial chordoma: a clinicopathologic analysis of six cases

Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis

The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer

The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix

Benign endometrial proliferations mimicking malignancies: a review of problematic entities in small biopsy specimens

The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future